Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
LA JOLLA PHARMACEUTICAL CO (LJPC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/06/2020 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress |
| 07/28/2020 |
GN
| Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company |
| 07/28/2020 |
GN
| La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc. |
| 06/24/2020 |
GN
| La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. |
| 04/13/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium |
| 04/07/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany |
| 04/06/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom |
| 04/03/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany |
| 04/02/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom |
| 03/13/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA??? (Angiotensin II) in Italy for Compassionate Use in Patients with Septic Shock Associated with COVID-19 |
| 03/02/2020 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 |
| 01/09/2020 |
GN
| La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019 |
| 11/25/2019 |
GN
| La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results |
| 11/12/2019 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress |
| 08/29/2019 |
GN
| La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II) |
| 07/23/2019 |
GN
| La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria |
| 06/28/2019 |
GN
| La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock |
| 06/06/2019 |
GN
| La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis |
| 05/06/2019 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress |
| 04/24/2019 |
GN
| La Jolla Pharmaceutical Company Announces U.S. FDA's Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria |
| 03/04/2019 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives |
| 02/14/2019 |
GN
| La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine's 48th Critical Care Congress |
| 01/07/2019 |
GN
| La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives |
| 01/04/2019 |
GN
| La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference |
| 10/24/2018 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018 |
| 10/18/2018 |
GN
| La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018 |
| 08/16/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasizes Economic Growth |
| 08/03/2018 |
GN
| La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA |
| 08/01/2018 |
GN
| La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018 |
| 06/25/2018 |
GN
| La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA™ (angiotensin II) |
| 05/21/2018 |
GN
| Recent Analysis Shows Engility, La Jolla Pharmaceutical, Freshpet, At Home Group, Denny's, and SP Plus Market Influences — Renewed Outlook, Key Drivers of Growth |
| 05/17/2018 |
GN
| La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association |
| 05/10/2018 |
GN
| La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners |
| 05/10/2018 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress |
|
|
|